Nouveaux hypolipémiants : prospectives = New lipid-lowering drugs: Future prospectsFARNIER, Michel.Thérapie (Paris). 2003, Vol 58, Num 1, pp 97-105, issn 0040-5957, 9 p.Article

Hypolipaemic effect of guanfacine: Two years' follow-upHAUGER-KLEVENE, J. H.Drugs under experimental and clinical research. 1984, Vol 10, Num 2, pp 133-140, issn 0378-6501Article

In vitro studies on the distribution of probucol among human plasma lipoproteinsSAIK URIEN; RIANT, P; ALBENGRES, E et al.Molecular pharmacology. 1984, Vol 26, Num 2, pp 322-327, issn 0026-895XArticle

Plantes à saponine et régulation des dyslipémies = Saponine inplants and dyslipemiasBERGERET, C.Cahiers de biothérapie (Paris). 1984, Num 81, pp 55-57, issn 0301-1178Article

Cardiac and hepatic acyl-CoA and acylcarnitine hydrolase activities in clofibrate-fed rabbitsMOORE, K. H; SOLOMON, F. J.Comparative biochemistry and physiology. C. Comparative pharmacology. 1985, Vol 80, Num 2, pp 355-359, issn 0306-4492Article

Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogsGARRETT, E. R; ALTMAYER, P.Journal of pharmaceutical sciences. 1985, Vol 74, Num 3, pp 295-299, issn 0022-3549Article

Hépatotoxicité des hypolipémiantsLARREY, Dominique.Hépato-gastro (Montrouge). 2004, Vol 11, Num 6, pp 407-413, issn 1253-7020, 7 p.Article

PANORAMA ACTUEL DES MEDICAMENTS HYPOLIPEMIANTSHELLER F; HARVENGT C.1980; BULL. SOC. PHARM. LILLE; ISSN 0366-3507; FRA; DA. 1980; VOL. 36; NO 3-4; PP. 209-219; BIBL. 3 P.Article

INDUCTION OF HEPATIC LONG-CHAIN ACYL-COA HYDROLASE BY CLOFIBRIC ACID ADMINISTRATIONKAWASHIMA Y; KATOH H; NAKAJIMA S et al.1983; BIOCHIMICA ET BIOPHYSICA ACTA; ISSN 0006-3002; NLD; DA. 1983; VOL. 752; NO 1; PP. 182-185; BIBL. 27 REF.Article

ESTUDIO CLINICO DEL EFECTO HIPOLIPEMIANTE DEL ACETATO DE FENOXITETRALINA (CH13437) = ETUDE CLINIQUE DES EFFETS HYPOLIPEMIANTS DE L'ACETATE DE PHENOXYTETRALINE (CH13437)1970; REV. MED. HOSP. COLONIA; MEX.; DA. 1970; VOL. 18; NO 104; PP. 133-136; BIBL. 6REF.Serial Issue

The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the FutureHAJHOSSEINY, R; SABIR, I; KHAVANDI, K et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 1, pp 64-73, issn 0009-9236, 10 p.Article

Rapid determination of clofibric acid in human plasma by high-performance liquid chromatographyPAILLET, M; DOUCET, D; MERDJEAN, H et al.Journal of chromatography. 1986, Vol 375, Num 1, pp 179-183, issn 0021-9673Article

Proceedings/Fenofibrate, a third-generation fibric acid derivative, symposium, Dallas TX, November 15, 1986BROWN, W. V.The American journal of medicine. 1987, Vol 83, Num 5, issn 0002-9343, 89 p., BConference Proceedings

Distinction entre patients bons synthétiseurs et bons absorbeurs pour optimiser le traitement hypocholestérolémiant : Thérapeutique = Distinction between good synthesizer and good absorber patients to optimize cholesterol-lowering therapyRADERMECKER, Régis P; SCHEEN, André J.Revue médicale suisse. 2006, Vol 2, Num 76, pp 1910-1915, issn 1660-9379, 6 p.Article

À la découverte de l'ézétimibe = EzetimibeWATKINS, C.La Lettre du cardiologue. 2004, Num 378, pp 44-45, issn 0761-5035, 2 p.Article

Lescol, vastin : Generic name : FluvastatinMALLARKEY, G.Current therapeutics. 1996, Vol 37, Num 4, pp 81-83, issn 0311-905XArticle

Current approaches to drug therapy for the hypercholesterolemic patientWITZTUM, J. L.Circulation (New York, N.Y.). 1989, Vol 80, Num 5, pp 1101-1114, issn 0009-7322, 14 p.Article

Suitability of laboratory animals for screening anti-hyperlipidemic agentsNEELA RAJWADE; DESAI, N. K; JOSHI, V. G et al.Journal of Postgraduate Medicine (Bombay). 1989, Vol 35, Num 3, pp 162-170, issn 0022-3859, 9 p.Article

The effects of hypolipidemic agents derived from procetofenic acid on the activity of superoxide dismutase and glutathione peroxidase and on malonyl dialdehyde production of rat liverCIRIOLO, M. R; ROSSI, L; MAVELLI, I et al.Arzneimittel-Forschung. 1984, Vol 34, Num 4, pp 465-467, issn 0004-4172Article

Drug treatment of hyperlipidemiaJONES, P; GOTTO, A. M. JR.Modern concepts of cardiovascular disease. 1984, Vol 53, Num 10, pp 53-58, issn 0026-7600Serial Issue

A REAPPRAISAL OF THE MECHANISMS OF HYPOCHOLESTEROLEMIC ACTION OF THERAPEUTIC AGENTSSODHI HS; KUDCHODKAR BJ; CLIFFORD C et al.1978; ADV. EXPER. MED. BIOL.; USA; DA. 1978; VOL. 109; PP. 331-345; BIBL. 33 REF.Conference Paper

POTENTIAL HYPOLIPIDEMIC AGENTS. IV. PREPARATION OF 4 NEW 5,6-DIHALONICOTINIC ACIDSGACEK M; GRONOWITZ S; HEDBOM C et al.1972; ACTA PHARM. SUECICA; SUEDE; DA. 1972; VOL. 9; NO 4; PP. 373-376; BIBL. 10REF.Serial Issue

DIE LANGZEITBEHANDLUNG DER VERSCHIEDENEN HYPERLIPIDAEMIEN MIT CLOFIBRAT. = TRAITEMENT AU LONG COURS DES DIFFERENTES HYPERLIPIDEMIES PAR LE CLOFIBRATESTUDLAR M; PICHLER O; KINDLER K et al.1975; WIEN. MED. WSCHR.; OESTERR.; DA. 1975; VOL. 125; NO 50-52; PP. 746-751; BIBL. 23 REF.Article

2.111.862 (B) (7138539). - 27OCTOBRE 1971. APPLICATION NOUVELLE DE DERIVES DE L'ADENOSINE N(6)-SUBSTITUESsdPatent

2.115.357 (B) (7141921). - 23NOVEMBRE 1971. NOUVEAUX DERIVES DE L'ACIDE NICOTINIQUEsdPatent